Category survey

Alzheimers sjukdom biomarkörer för molekylära mekanismer, diagnostik och theragnostik. Alzheimer’s disease – biomarkers for molecular mechanisms, diagnostics and theragnostics Investments < €500k Sweden 2016    

EXPLORING THE MECHANISM BEHIND METABOLIC RISK FACTORS FOR ALZHEIMER DISEASE. AN INTEGRATIVE APPROACH TO TYPIFY DISEASE PATHWAYS, OPTMISE DIAGNOSIS AND TREATMENT. Investments < €500k Sweden 2016    

Towards Neurotrophic therapes in Alzheimer’s disease Investments < €500k Sweden 2016    

The role of cerebral small vessel disease in cognitive aging Investments < €500k Sweden 2016    

Healthy ageing Investments < €500k Sweden 2016    

Structure and volume of the olfactory brain: Relationships to olfactory dysfunction, cognitive decline and prospective dementia. Investments < €500k Sweden 2016    

Human Monoclonal Antibodies for the Therapy of Transthyretin Amyloidosis Diseases Investments < €500k Sweden 2016    

Is Chronic Arsenic Poisoning Associated With Protein Aggregate Pathology? Investments < €500k Sweden 2016    

Subtle Change Detection and Quantification in Magnetic Resonance Neuroimaging Investments < €500k Sweden 2016    

Optimizing drug treatment in old age: a novel translational research project Investments < €500k Sweden 2016    

Understanding stroke, vascular dementia and cognitive aging through new techniques and models for assessment of cerebral blood flow and cerebrospinal fluid dynamics Investments < €500k Sweden 2016    

Functional analysis of neuronal circuits in health and disease Investments < €500k Sweden 2016    

3D Memories promoting inhibited potential in design processes Investments < €500k Sweden 2016    

Development of a diamond waveguide sensor for ultra sensitive chemical analysis using tunable mid-IR quantum cascade lasers Investments < €500k Sweden 2016    

Evaluation of vascular determinant for cognitive decline in old age: Coordinated analysis of within-person associations using data from four longitudinal aging studies Investments < €500k Sweden 2016    

Early detection of dementia: finding the best combination of cognitive and non-cognitive markers of preclinical dementia Investments < €500k Sweden 2016    

Do we live longer healthy or with disease? A comparison of 85-90 year olds today and 2 decades ago. Investments < €500k Sweden 2016    

A prospective cohort study on oral health and risks of dementia, cardiovascular diseases and inflammatory bowel diseases Investments < €500k Sweden 2016    

21st Century EURODEM Investments < €500k Sweden 2016    

Improving balance and physical activity in elderly with Parkinson’s disease – long-term efficacy and effectiveness in a clinical practise of the HiBalance program Investments < €500k Sweden 2016    

Memory training for persons with Parkinson’s diesease Investments < €500k Sweden 2016    

How can people with obesity combat dementia? A lifespan approach Investments < €500k Sweden 2016    

High-Intensity Functional Exercise for Older People with Dementia: A Randomized Controlled Trial Investments < €500k Sweden 2016    

Identifying novel anti-amyloid targets in psychogeriatric disorders Investments < €500k Sweden 2016    

Studies on amyloid toxicity Investments < €500k Sweden 2016    

Mechanisms of synapse damage in Alzheimer disease Investments < €500k Sweden 2016    

The role of astrocytes in development and progression of Alzheimer’s disease Investments < €500k Sweden 2016    

Development of novel strategy for Alzheimer disease therapy based on modulation of molecular chaperone networks Investments < €500k Sweden 2016    

Human genetic studies of Alzheimer disease and other dementias Investments < €500k Sweden 2016    

Neuropeptide signaling in health and disease Investments < €500k Sweden 2016    

Development of new therapeutics for Alzheimer´s disease Investments < €500k Sweden 2016    

Deciphering the role and importance of altered glycosylations in neurodegenerative and neurometabolic diseases Investments < €500k Sweden 2016    

Time course of early pathophysiological changes and biomarkers in Alzheimer´s disease and related disorders- implications for preventive therapy. Investments < €500k Sweden 2016    

Extrasynaptic glutamate signalling and synapoptosis in brain development and degeneration Investments < €500k Sweden 2016    

Synaptic mechanisms implicated in Alzheimer´s disease Investments < €500k Sweden 2016    

Molecular mechanisms of Abeta aggregation in Alzheimer Disease Investments < €500k Sweden 2016    

Omega-3 fatty acids and vitamin E complex in prodromal Alzheimer disease: clinical trials in older adults Investments < €500k Sweden 2016    

In vivo and in vitro Drosophila models to study the role of heparan sulfate in Alzheimer´s disease pathogenesis Investments < €500k Sweden 2016    

Immunological and histochemical assessment of an Alzheimer´s vaccine Investments < €500k Sweden 2016    

Polymorphism in PrP and its relevance for moose and public health Investments < €500k Sweden 2016    

Mechanisms controlling sequestration and detoxification of Huntingtin proteins in yeast (Saccharomyces cerevisiae) Investments < €500k Sweden 2016    

Peripheral tissue molecular signatures – providing new insights into Huntingtons Disease pathology Investments < €500k Sweden 2016    

Development of new biomarkers and brain imaging techniques for Dementia and Parkinsonian disorders: key tools for exploring etiology to improve diagnosis and advance drug development Investments < €500k Sweden 2016    

Functional neuroproteomic changes associated with L-Dopa-induced dyskinesia in Parkinson´s disease Investments < €500k Sweden 2016    

Mass Spectrometry Imaging with Nano-DESI: New Methods and Application to Neurodegenerative Diseases Investments < €500k Sweden 2016    

Computational studies of the structural and chemical biology of A2A adenosine and D2 dopamine receptor signaling Investments < €500k Sweden 2016    

Targeting NMDA receptor dysfunctions in Parkinson´s disease Investments < €500k Sweden 2016    

Functional circuitry analysis of the subthalamic nucleus in mice: Relevance for Deep Brain Simulation in Parkinson´s disease. Investments < €500k Sweden 2016    

BALANCING ENDOCANNABINOID-MEDIATED PLASTICITY WITH NICOTINE Investments < €500k Sweden 2016    

Biophysical studies of the amyloid beta peptide – structure conversion, aggregation pathways and molecular interactions Investments < €500k Sweden 2016